Biogen, UPMC Health Plan Contract Links PROs to Drug Reimbursement for Multiple Sclerosis
January 29, 2020
Biogen and UPMC Health Plan have signed off on a value-based contract that would link reimbursement to patient-reported outcomes for multiple sclerosis drugs Tecfidera and Avonex, The Pink Sheet reports.
According to the report, the arrangement will look at “outcomes related to worsening physical disability.”
To read more on The Pink Sheet, click here.
